Curated News
By: NewsRamp Editorial Staff
March 13, 2026
HeartBeam Advances Cardiac Care with FDA-Cleared ECG Tech and Market Launch
TLDR
- HeartBeam's FDA-cleared 12-lead ECG software and commercial partnerships offer investors early access to a potentially disruptive cardiac monitoring technology.
- HeartBeam's technology synthesizes 3D ECG signals into 12-lead ECGs using a cable-free device, with FDA clearance and ongoing pilot studies validating its approach.
- HeartBeam's portable cardiac monitoring technology enables early heart attack detection outside medical facilities, potentially saving lives and improving access to cardiac care.
- HeartBeam is developing a wearable patch that creates 12-lead ECGs from 3D signals, collaborating with Mount Sinai to enhance detection with AI algorithms.
Impact - Why it Matters
This news matters because it represents a significant leap forward in accessible and remote cardiac monitoring, potentially saving lives by enabling earlier detection of heart conditions like arrhythmias and heart attacks outside clinical settings. For patients, HeartBeam's portable 3D ECG technology could reduce the need for frequent hospital visits, lower healthcare costs, and provide peace of mind through continuous, actionable insights into heart health. For the medical community, it offers a tool to improve diagnostic accuracy and preventive care, while for investors, it signals growth in the medtech sector driven by AI and regulatory approvals. Given the global burden of cardiovascular diseases, innovations like this could transform public health outcomes by making advanced cardiac care more convenient and widespread.
Summary
HeartBeam (NASDAQ: BEAT), a pioneering medical technology company, has announced significant financial and operational milestones for the fourth quarter and full year ending December 31, 2025, marking a transformative phase in cardiac care. The company's progress follows the crucial U.S. Food and Drug Administration (FDA) 510(k) clearance of its innovative 12-lead electrocardiogram (ECG) synthesis software in December 2025, a development that positions HeartBeam at the forefront of portable cardiac diagnostics. This regulatory milestone has enabled the company to initiate a limited market launch targeting concierge and preventive cardiology groups, while also securing its first commercial partnership with ClearCardio™. Additionally, HeartBeam has enrolled initial patients in its ALIGN-ACS pilot study, which evaluates the HeartBeam System for heart attack detection, and has completed a prototype for an extended-wear 12-lead ECG patch. The company has further strengthened its technological foundation through a strategic collaboration with the Icahn School of Medicine at Mount Sinai to advance AI-enabled ECG algorithms and has appointed a new chief commercial officer to drive growth initiatives, underscoring its commitment to commercializing its groundbreaking platform.
At the core of HeartBeam's mission is the development of the first-ever cable-free device capable of collecting ECG signals in three dimensions from non-coplanar directions and synthesizing them into a comprehensive 12-lead ECG. This platform technology is designed for portable use, allowing patients to receive actionable heart intelligence wherever they are, thereby enabling physicians to identify cardiac health trends and acute conditions outside traditional medical facilities. The company's 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for the 12-lead ECG synthesis software in December 2025, holds over 20 issued patents and aims to redefine the future of cardiac health management by providing powerful cardiac insights. For more details, investors can access the full press release via the provided hyperlink, and additional updates are available in the company's newsroom, highlighting the role of platforms like AINewsWire in disseminating such advancements within the Dynamic Brand Portfolio of IBN.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam Advances Cardiac Care with FDA-Cleared ECG Tech and Market Launch
